NAV

Landiolol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Landiolol is an ultra short-acting selective beta-blocker used for rapid ventricular rate control in cases of supraventricular tachycardia.

Generic Name
Landiolol
DrugBank Accession Number
DB12212
Background

Landiolol is a rapid-acting beta-blocker used for rapid ventricular rate control.

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 509.6
Monoisotopic: 509.273715228
Chemical Formula
C25H39N3O8
Synonyms
  • Landiolol
  • Landiololum
External IDs
  • AOP-200704
  • AOP200704
  • LDLL-600
  • LDLL600
  • ONO 1101
  • ONO-1101
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofTachycardia, supraventricular•••••••••••••••••••••• ••••••• ••• ••••••••• •••••••••• ••••••••• •••••••••••
Treatment ofNoncompensatory sinus tachycardia•••••••••••••••••••••• ••••••• ••• ••••••••• •••••••••• ••••••••• •••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbaloparatideAbaloparatide may increase the hypotensive activities of Landiolol.
AbataceptThe metabolism of Landiolol can be increased when combined with Abatacept.
AbirateroneThe metabolism of Landiolol can be decreased when combined with Abiraterone.
AcebutololAcebutolol may increase the arrhythmogenic activities of Landiolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Landiolol.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Landiolol hydrochlorideG8HQ634Y17144481-98-1DLPGJHSONYLBKP-IKGOIYPNSA-N
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
SibboranPowder, for solution300 mg / vialIntravenousTrimedic Therapeutics Inc.Not applicableNot applicableCanada flag

Categories

ATC Codes
C07AB14 — Landiolol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as morpholine carboxylic acids and derivatives. These are heterocyclic compounds containing a morpholine ring substituted by one or more carboxylic acid groups (or derivative thereof).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxazinanes
Sub Class
Morpholines
Direct Parent
Morpholine carboxylic acids and derivatives
Alternative Parents
Phenoxy compounds / Phenol ethers / Ketals / Alkyl aryl ethers / Fatty acid esters / 1,3-dioxolanes / Ureas / Secondary alcohols / 1,2-aminoalcohols / Carboxylic acid esters
show 10 more
Substituents
1,2-aminoalcohol / Acetal / Alcohol / Alkyl aryl ether / Amine / Amino acid or derivatives / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carbonic acid derivative
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
62NWQ924LH
CAS number
133242-30-5
InChI Key
WMDSZGFJQKSLLH-RBBKRZOGSA-N
InChI
InChI=1S/C25H39N3O8/c1-25(2)35-18-22(36-25)17-34-23(30)8-5-19-3-6-21(7-4-19)33-16-20(29)15-26-9-10-27-24(31)28-11-13-32-14-12-28/h3-4,6-7,20,22,26,29H,5,8-18H2,1-2H3,(H,27,31)/t20-,22+/m0/s1
IUPAC Name
[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-{4-[(2S)-2-hydroxy-3-({2-[(morpholine-4-carbonyl)amino]ethyl}amino)propoxy]phenyl}propanoate
SMILES
CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1

References

General References
  1. BASG Product Information: Rapibloc (landiolol hydrochloride) for infusion [Link]
PubChem Compound
114905
PubChem Substance
347828494
ChemSpider
102855
ChEBI
135809
ChEMBL
CHEMBL1742466
ZINC
ZINC000003929810
Wikipedia
Landiolol

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4Unknown StatusTreatmentAtrial Fibrillation / Surgery, Cardiac1
3CompletedDiagnosticCoronary Artery Disease (CAD)1
3CompletedPreventionAtrial Fibrillation / Surgery, Cardiac1
3CompletedTreatmentAtrial Fibrillation1
3RecruitingPreventionAtrial Fibrillation / Postoperative Complications1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntravenous600 MG
Injection, solution, concentrateIntravenous20 mg/2ml
Injection, powder, for solutionIntravenous300 mg
Powder, for solutionIntravenous300 mg / vial
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.334 mg/mLALOGPS
logP0.44ALOGPS
logP0.35Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)14.04Chemaxon
pKa (Strongest Basic)8.79Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area127.82 Å2Chemaxon
Rotatable Bond Count14Chemaxon
Refractivity131.29 m3·mol-1Chemaxon
Polarizability56.5 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0003960000-8f450c80f18d79d59d3d
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0pdl-2319420000-3dcc0646eb5fb3ce152a
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fal-2001900000-66bd59cc18fd05a6582a
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-2419400000-13e4312fa0e84aceaf5d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0f80-5628910000-1c7db428457e901b2a20
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-066u-6958520000-37b9dea90d407d5595c6
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-249.3207856
predicted
DarkChem Lite v0.1.0
[M-H]-207.84413
predicted
DeepCCS 1.0 (2019)
[M+H]+249.7694856
predicted
DarkChem Lite v0.1.0
[M+H]+210.2397
predicted
DeepCCS 1.0 (2019)
[M+Na]+249.6353856
predicted
DarkChem Lite v0.1.0
[M+Na]+216.15222
predicted
DeepCCS 1.0 (2019)

Enzymes

Details1. Cytochrome P450 2D6
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A: Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):981-1007. doi: 10.1517/17425255.2.6.981 . [Article]
  2. Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22. [Article]
  3. Iwaki M, Niwa T, Bandoh S, Itoh M, Hirose H, Kawase A, Komura H: Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. doi: 10.1016/j.dmpk.2016.08.007. Epub 2016 Sep 2. [Article]

Drug created at October 20, 2016 21:37 / Updated at May 21, 2021 10:28